Chinese University of Hong Kong: Hepatitis B, Chronic trials
The registry lists 12 Hepatitis B, Chronic studies with Chinese University of Hong Kong as lead sponsor. 4 are open to participants now and 0 have results posted.
Phase 2 1Phase 4 4No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Treatment Prioritisation and Cost-Effectiveness Analysis for HBV Cure - Real-World Evidence from a Territory-Wide CohortNot yet recruitingNCT06627608
- Hepatitis Inequalities StudyNot yet recruitingNCT06596213
- SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes MellitusRecruitingNCT06364930Phase 4
- Prospective Evaluation of a Fast-track Treatment Pathway for Patients With Chronic Hepatitis B Under Primary CareRecruitingNCT04904900
- Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus EntecavirActive, not recruitingNCT05423834
- Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic DiseaseTerminatedNCT02128503Not applicable
- Serum Hepatitis B Surface Antigen Levels to Guide the Stopping of Entecavir in HBeAg-negative Chronic Hepatitis BCompletedNCT02069678
- An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue TherapyCompletedNCT02068365Phase 4
- Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal DiseasesWithdrawnNCT02049736Not applicable
- Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)CompletedNCT00338780Phase 4
- Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B PatientsCompletedNCT00226447Phase 2
- Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral TreatmentCompletedNCT00226382Phase 4